Cargando…

Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants

OBJECTIVE: Congenital adrenal hyperplasia (CAH) is the most common form of primary adrenal insufficiency in children. Neonatal screening for CAH is effective in detecting the salt-wasting (SW) form and in reducing mortality. In this study, our aim was to estimate the incidence of CAH in Turkey and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Güran, Tülay, Tezel, Başak, Gürbüz, Fatih, Selver Eklioğlu, Beray, Hatipoğlu, Nihal, Kara, Cengiz, Şimşek, Enver, Çizmecioğlu, Filiz Mine, Ozon, Alev, Baş, Firdevs, Aydın, Murat, Darendeliler, Feyza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398187/
https://www.ncbi.nlm.nih.gov/pubmed/30111524
http://dx.doi.org/10.4274/jcrpe.galenos.2018.2018.0117
_version_ 1783399537919918080
author Güran, Tülay
Tezel, Başak
Gürbüz, Fatih
Selver Eklioğlu, Beray
Hatipoğlu, Nihal
Kara, Cengiz
Şimşek, Enver
Çizmecioğlu, Filiz Mine
Ozon, Alev
Baş, Firdevs
Aydın, Murat
Darendeliler, Feyza
author_facet Güran, Tülay
Tezel, Başak
Gürbüz, Fatih
Selver Eklioğlu, Beray
Hatipoğlu, Nihal
Kara, Cengiz
Şimşek, Enver
Çizmecioğlu, Filiz Mine
Ozon, Alev
Baş, Firdevs
Aydın, Murat
Darendeliler, Feyza
author_sort Güran, Tülay
collection PubMed
description OBJECTIVE: Congenital adrenal hyperplasia (CAH) is the most common form of primary adrenal insufficiency in children. Neonatal screening for CAH is effective in detecting the salt-wasting (SW) form and in reducing mortality. In this study, our aim was to estimate the incidence of CAH in Turkey and to assess the characteristics and efficacy of the adopted newborn CAH screening strategy. METHODS: A pilot newborn CAH screening study was carried out under the authority of the Turkish Directorate of Public Health. Newborn babies of ≥32 gestational weeks and ≥1500 gr birth weight from four cities, born between March 27-September 15, 2017 were included in the study. Screening protocol included one sample two-tier testing. In the first step, 17α-hydroxyprogesterone (17-OHP) was measured by fluoroimmunoassay in dried blood spots (DBS) obtained at 3-5 days of life. The cases with positive initial screening were tested by steroid profiling in DBS using a liquid chromatography-tandem mass spectrometry method to measure 17-OHP, 21-deoxycortisol (21-S), cortisol (F), 11-deoxycortisol and androstenedione as a second-tier test. The babies with a steroid ratio (21-S+17-OHP)/F of ≥0.5 were referred to pediatric endocrinology clinics for diagnostic assessment. RESULTS: 38,935 infants were tested, 2265 (5.82%) required second-tier testing and 212 (0.54%) were referred for clinical assessment, six of whom were diagnosed with CAH (four males, two females). Four cases were identified as SW 21-hydroxylase deficiency (21-OHD) (two males, two females). One male baby had simple virilizing 21-OHD and one male baby had 11-OHD CAH. The incidence of classical 21-OHD in the screened population was 1:7,787. CONCLUSION: The incidence of CAH due to classical 21-OHD is higher in Turkey compared to previous reports. We, therefore, suggest that CAH be added to the newborn screening panel in Turkey. The use of steroid profiling as a second-tier test was found to improve the efficacy of the screening and reduce the number of false-positives.
format Online
Article
Text
id pubmed-6398187
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-63981872019-03-22 Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants Güran, Tülay Tezel, Başak Gürbüz, Fatih Selver Eklioğlu, Beray Hatipoğlu, Nihal Kara, Cengiz Şimşek, Enver Çizmecioğlu, Filiz Mine Ozon, Alev Baş, Firdevs Aydın, Murat Darendeliler, Feyza J Clin Res Pediatr Endocrinol Original Article OBJECTIVE: Congenital adrenal hyperplasia (CAH) is the most common form of primary adrenal insufficiency in children. Neonatal screening for CAH is effective in detecting the salt-wasting (SW) form and in reducing mortality. In this study, our aim was to estimate the incidence of CAH in Turkey and to assess the characteristics and efficacy of the adopted newborn CAH screening strategy. METHODS: A pilot newborn CAH screening study was carried out under the authority of the Turkish Directorate of Public Health. Newborn babies of ≥32 gestational weeks and ≥1500 gr birth weight from four cities, born between March 27-September 15, 2017 were included in the study. Screening protocol included one sample two-tier testing. In the first step, 17α-hydroxyprogesterone (17-OHP) was measured by fluoroimmunoassay in dried blood spots (DBS) obtained at 3-5 days of life. The cases with positive initial screening were tested by steroid profiling in DBS using a liquid chromatography-tandem mass spectrometry method to measure 17-OHP, 21-deoxycortisol (21-S), cortisol (F), 11-deoxycortisol and androstenedione as a second-tier test. The babies with a steroid ratio (21-S+17-OHP)/F of ≥0.5 were referred to pediatric endocrinology clinics for diagnostic assessment. RESULTS: 38,935 infants were tested, 2265 (5.82%) required second-tier testing and 212 (0.54%) were referred for clinical assessment, six of whom were diagnosed with CAH (four males, two females). Four cases were identified as SW 21-hydroxylase deficiency (21-OHD) (two males, two females). One male baby had simple virilizing 21-OHD and one male baby had 11-OHD CAH. The incidence of classical 21-OHD in the screened population was 1:7,787. CONCLUSION: The incidence of CAH due to classical 21-OHD is higher in Turkey compared to previous reports. We, therefore, suggest that CAH be added to the newborn screening panel in Turkey. The use of steroid profiling as a second-tier test was found to improve the efficacy of the screening and reduce the number of false-positives. Galenos Publishing 2019-03 2019-02-20 /pmc/articles/PMC6398187/ /pubmed/30111524 http://dx.doi.org/10.4274/jcrpe.galenos.2018.2018.0117 Text en ©Copyright 2019 by Turkish Pediatric Endocrinology and Diabetes Society | The Journal of Clinical Research in Pediatric Endocrinology published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Güran, Tülay
Tezel, Başak
Gürbüz, Fatih
Selver Eklioğlu, Beray
Hatipoğlu, Nihal
Kara, Cengiz
Şimşek, Enver
Çizmecioğlu, Filiz Mine
Ozon, Alev
Baş, Firdevs
Aydın, Murat
Darendeliler, Feyza
Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants
title Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants
title_full Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants
title_fullStr Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants
title_full_unstemmed Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants
title_short Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants
title_sort neonatal screening for congenital adrenal hyperplasia in turkey: a pilot study with 38,935 infants
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398187/
https://www.ncbi.nlm.nih.gov/pubmed/30111524
http://dx.doi.org/10.4274/jcrpe.galenos.2018.2018.0117
work_keys_str_mv AT gurantulay neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants
AT tezelbasak neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants
AT gurbuzfatih neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants
AT selverekliogluberay neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants
AT hatipoglunihal neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants
AT karacengiz neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants
AT simsekenver neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants
AT cizmecioglufilizmine neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants
AT ozonalev neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants
AT basfirdevs neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants
AT aydınmurat neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants
AT darendelilerfeyza neonatalscreeningforcongenitaladrenalhyperplasiainturkeyapilotstudywith38935infants